Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 11/20 | 0.47 |
| ▸ | EDNRA | P25101 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7436226 | 1.00 | EDNRB (0.47) | EDNRBEDNRAALDH1A1MAPTHDAC1 | |
| SCHEMBL7436229 | 1.00 | EDNRB (0.47) | EDNRBEDNRAALDH1A1MAPTHDAC1 | |
| SCHEMBL8724866 | 0.93 | TACR1 (0.45) | EDNRBEDNRAALDH1A1MAPTTACR1 | |
| SCHEMBL8724868 | 0.93 | TACR1 (0.45) | EDNRBEDNRAALDH1A1MAPTTACR1 | |
| SCHEMBL8726256 | 0.89 | NPY5R (0.46) | EDNRBEDNRA | |
| SCHEMBL8726260 | 0.89 | NPY5R (0.46) | EDNRBEDNRA | |
| SCHEMBL7451075 | 0.88 | ALDH1A1 (0.50) | EDNRBEDNRAALDH1A1MAPT | |
| SCHEMBL16907004 | 0.88 | ALDH1A1 (0.50) | EDNRBEDNRAALDH1A1MAPT | |
| SCHEMBL7451078 | 0.88 | ALDH1A1 (0.50) | EDNRBEDNRAALDH1A1MAPT | |
| SCHEMBL8490486 | 0.87 | SLC7A5 (0.40) | EDNRBEDNRAHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160331783-A1 | BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| US-20160331783-A1 | BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| WO-2015106242-A2 | BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331783-A1 | BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | HBB, HBG2, HBG1 | EDNRB 259/4885EDNRA 205/4885ALDH1A1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.